USP33 can directly target parkin RBR E3 ubiquitin protein ligase (PRKN), and knockdown of USP33 enhances PRKN-mediated mitophagy,99 providing a new therapeutic strategy for the treatment of Parkinson's disease. Here, PRKN is linked to Parkinson disease.